Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.81B P/E - EPS this Y - Ern Qtrly Grth -
Income -342.31M Forward P/E -10.54 EPS next Y - 50D Avg Chg 1.00%
Sales 1.01M PEG - EPS past 5Y - 200D Avg Chg 63.00%
Dividend N/A Price/Book 4.78 EPS next 5Y - 52W High Chg -8.00%
Recommedations 3.00 Quick Ratio 16.56 Shares Outstanding 50.07M 52W Low Chg 220.00%
Insider Own 0.70% ROA -22.13% Shares Float 48.20M Beta -0.19
Inst Own 92.52% ROE -36.80% Shares Shorted/Prior 2.14M/2.86M Price 76.01
Gross Margin 100.00% Profit Margin - Avg. Volume 1,897,877 Target Price 71.50
Oper. Margin -34,185.81% Earnings Date Nov 7 Volume 2,843,392 Change 0.00%
About Turning Point Therapeutics, Inc

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

TPTX Chatroom

User Image Auphiliate Posted - 4 hours ago

@Maxwell_Smart I’m far from being an expert…. That said, I’m also in $TPTX for trial results this fall, $TGTX for increase within ~ 1.5 years due to their partnership clause which allows a bo within two years (now ~ 1.5), and tiny stake in $EPIX. Watching a couple of others. Stuck with a few thousand shares in $SRNEQ and $SCLX, awaiting results of CH11 🤦‍♀️. My 401K is in biotechnology and oil( energy) mutual funds. Rec’d a very small amt. of bitcoin for Christmas from my millionnaire bitcoin son and will cost average there, over time! Wish me luck—and you too! 😊

User Image Quantumup Posted - 1 day ago

Jefferies⬆️ $NUVB Buy/$10 was Hold/$1.4 =$3B valuation or 300% upside/not a stretch if pivotal P2B ROS1 lung cancer data is confirmed this yr/early data looks as good as $NUVL/ $TPTX which are $4-5B valuations. This is an under-followed small cap w/ new story w/ this new Tx. $bmy

User Image kubota2323 Posted - 6 days ago

$MAIA hopefully can turn into $TPTX in time.

User Image Oncinvestor Posted - 1 month ago

@junkiegite @markovb343 @sulljd74 $tptx doesn’t have as good of a ROS1 inhibitor as $nuvl and $nuvl will leap frog lorlatinib in ALK and eventually alectinib S well because of its side effect profile. Wouldn’t be surprised to see a buy out in the next two years pending data

User Image TrendyChart Posted - 4 months ago

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/17/2023 at 4:00PM | Are you looking for a positive or negative earnings outcome?

User Image TrendyChart Posted - 4 months ago

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/17/2023 at 4:00PM | Do you have a rosy or gloomy earnings perspective for this stock?

User Image TrendyChart Posted - 10/31/23

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/10/2023 at 4:00PM | What's your take on the earnings potential of this stock?

User Image TrendyChart Posted - 10/31/23

Upcoming Earnings Report: $TPTX Turning Point will be reporting on 11/10/2023 at 4:00PM | Are you leaning towards a positive or negative earnings forecast?

User Image Oncinvestor Posted - 5 months ago

@illdefinedmind patients being treated with reprotrectinib are already having to switch to $NUVL’s inhibitor because of mutations (porter discussed this at recent conferences). ALK is a much bigger market with lots of room for improvements. I take alectinib as an ALK pos patient but many of my friends find lorlatinib side effects to be brutal. $tptx had an alk inhibitor too but it was too toxic.

User Image Oncinvestor Posted - 5 months ago

@illdefinedmind $BMY bought $TPTX for $4 billion plus on ROS1 data alone. Big companies will want these drugs before they are approved.

User Image mackinvestor Posted - 7 months ago

$BPMC Not worried about $BPMC Swings in $BPMC can be wild From 59 on June 3, 2022 (day of $BMY $TPTX buyout) to 45 on June 14 & 60 on June 24 Wish management would do something "transformative" to take control away from algos, MM's, Citadel Securities, etc.

User Image Nostradamus696 Posted - 11 months ago

$SGEN $TPTX $SRRA $MYOV. Altimmune smells like a buyout too. I would know 😉

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

User Image risenhoover Posted - 1 year ago

$TPTX TPTX / Turning Point Therapeutics Inc Price Target Updated https://fintel.io/sfo/us/tptx

User Image Marvind Posted - 1 year ago

$TPTX .777 that sounds lucky to me

User Image macroaxis Posted - 1 year ago

$TPTX - Turning Point calls open interest is sliding https://www.macroaxis.com/stock-options/TPTX/Turning-Point-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits

User Image stockilluminati Posted - 1 year ago

$TPTX https://www.stockilluminati.com/tptx/news.php - Grassroots Support for Why the Nativity? Has Been Tremendous

User Image biotickr Posted - 1 year ago

Drug pipeline for $TPTX excites me. A lot. Screenshot from https://biotickr.com/biotech-stocks/united-states-of-america/tptx-turning-point-therapeutics-inc

User Image fla Posted - 1 year ago

$TPTX [15s. delayed, acc.~90%, always check] Earnings Release 2022-07-27T10:59:00: Q2: Non-GAAP EPS of $1.93, GAAP EPS of $0.66, Revenue $ https://s.flashalert.me/1BYDQ

User Image macroaxis Posted - 10/29/22

$TPTX - Implied volatility is down to 11.1591 for Turning Point https://www.macroaxis.com/stock-options/TPTX/Turning-Point-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits

Analyst Ratings
SVB Leerink Market Perform Jun 13, 22
Cowen & Co. Market Perform Jun 6, 22
HC Wainwright & Co. Neutral Jun 6, 22
Wedbush Neutral Jun 3, 22
Goldman Sachs Buy May 24, 22
B of A Securities Buy May 20, 22
SVB Leerink Outperform May 11, 22
HC Wainwright & Co. Buy Mar 22, 22
Stifel Hold Mar 1, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Feb 09 Sell 36.3 397 14,411 3,448 02/11/22
Partridge Andrew John EVP & Chief Commerci.. EVP & Chief Commercial Officer Feb 09 Sell 36.3 221 8,022 22,078 02/11/22
North Annette EVP & General Counse.. EVP & General Counsel Feb 09 Sell 36.3 669 24,285 11,696 02/11/22
Hirmand Mohammad EVP & Chief Medical.. EVP & Chief Medical Officer Feb 09 Sell 36.3 669 24,285 6,838 02/11/22
Countouriotis Athena President & CEO President & CEO Feb 09 Sell 36.3 2,971 107,847 47,930 02/11/22
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Aug 31 Sell 80 10,000 800,000 12,365 08/31/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Aug 31 Option 17 10,000 170,000 22,365 08/31/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Mar 24 Option 4.49 28,435 127,673 32,551 03/24/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Mar 24 Sell 100.99 28,435 2,871,651 4,116 03/24/21
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Mar 05 Sell 106.52 35,550 3,786,786 3,845 03/05/21
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Mar 05 Option 51.28 35,550 1,823,004 39,395 03/05/21
Countouriotis Athena President & CEO President & CEO Feb 11 Option 3.2 60,000 192,000 59,137 02/11/21
Countouriotis Athena President & CEO President & CEO Feb 11 Sell 137.48 60,000 8,248,800 50,195 02/11/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Feb 02 Option 17 25,000 425,000 9,016 02/02/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Feb 02 Sell 127.14 25,000 3,178,500 02/02/21
Larson Yi EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Option 54.03 30,000 1,620,900 17,002 02/02/21
Larson Yi EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 127.27 30,000 3,818,100 2,704 02/02/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Jan 08 Option 4.49 28,438 127,687 32,246 01/08/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Jan 08 Sell 121.97 31,238 3,810,099 1,008 01/08/21
Hirmand Mohammad EVP and Chief Medica.. EVP and Chief Medical Officer Jan 05 Option 54.73 10,000 547,300 1,537 01/05/21
Hirmand Mohammad EVP and Chief Medica.. EVP and Chief Medical Officer Jan 05 Sell 120.95 10,300 1,245,785 284 01/05/21